KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Other Non-Current Assets (2016 - 2019)

Pacira BioSciences has reported Other Non-Current Assets over the past 10 years, most recently at $560000.0 for Q1 2019.

  • For Q1 2019, Other Non-Current Assets fell 26.22% year-over-year to $560000.0; the TTM value through Mar 2019 reached $560000.0, down 26.22%, while the annual FY2018 figure was $657000.0, 20.36% down from the prior year.
  • Other Non-Current Assets for Q1 2019 was $560000.0 at Pacira BioSciences, down from $657000.0 in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $2.6 million in Q3 2015 and troughed at $406000.0 in Q4 2015.
  • A 5-year average of $945470.6 and a median of $657000.0 in 2018 define the central range for Other Non-Current Assets.
  • Biggest five-year swings in Other Non-Current Assets: tumbled 84.31% in 2015 and later soared 53.69% in 2016.
  • Year by year, Other Non-Current Assets stood at $406000.0 in 2015, then surged by 53.69% to $624000.0 in 2016, then soared by 32.21% to $825000.0 in 2017, then dropped by 20.36% to $657000.0 in 2018, then dropped by 14.76% to $560000.0 in 2019.
  • Business Quant data shows Other Non-Current Assets for PCRX at $560000.0 in Q1 2019, $657000.0 in Q4 2018, and $747000.0 in Q3 2018.